SCHEMBL4395076

SCHEMBL4395076

O=C1c2cc3ccccc3cc2C(=O)C1(O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 14/20 0.65
CA2 P00918 14/20 0.65
CA7 P43166 14/20 0.65
CA9 Q16790 14/20 0.65
ALDH1A1 P00352 2/20 0.65
TSHR P16473 2/20 0.65
MAPK1 P28482 2/20 0.65
CASP1 P29466 2/20 0.65
ALOX12 P18054 1/20 0.65
RECQL P46063 1/20 0.65
BACE1 P56817 1/20 0.65
EHMT2 Q96KQ7 1/20 0.65
L3MBTL1 Q9Y468 1/20 0.65
CA4 P22748 3/20 0.52
GSTP1 P09211 1/20 0.40
NQO1 P15559 1/20 0.40
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
CASP7 P55210 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6363255 0.98 CA1 (0.62) CA1CA2CA7CA9ALDH1A1
SCHEMBL14575653 0.96 CA1 (0.60) CA1CA2CA7CA9ALDH1A1
SCHEMBL29350272 0.79 CA1 (1.00) CA1CA2CA7CA9ALDH1A1
SCHEMBL3658029 0.79 CA1 (1.00) CA1CA2CA7CA9ALDH1A1
SCHEMBL17986 0.79 CA1 (1.00) CA1CA2CA7CA9ALDH1A1
SCHEMBL24756167 0.79 CA1 (0.61) CA1CA2CA7CA9ALDH1A1
Water SCHEMBL592691 0.77 CA1 (0.94) CA1CA2CA7CA9ALDH1A1
Ammonia Solution, Strong SCHEMBL1286269 0.77 CA1 (0.94) CA1CA2CA7CA9ALDH1A1
Hydrochloric Acid SCHEMBL28516500 0.77 CA1 (0.94) CA1CA2CA7CA9ALDH1A1
SCHEMBL4921601 0.77 CA1 (0.94) CA1CA2CA7CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3597184-B1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES KOREA RES INST CHEMICAL TECH (KR) 2026-03-04 EP disclosed
EP-2722042-B1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES KOREA RES INST CHEMICAL TECH (KR) 2019-05-29 EP disclosed
US-9890133-B2 Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R&D (BE) 2018-02-13 US disclosed
US-20160297789-A1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2016-10-13 US disclosed
US-9464067-B2 Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2016-10-11 US disclosed
US-20140114068-A1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2014-04-24 US disclosed
EP-2722042-A2 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES Korea Research Institute of Chemical Technology (KR) 2014-04-23 EP disclosed
US-8338028-B2 Electrode active material for power storage device, power storage device, and electronic and transport devices PANASONIC CORPORATION (JP) 2012-12-25 US disclosed
US-20100196758-A1 ELECTRODE ACTIVE MATERIAL FOR POWER STORAGE DEVICE, POWER STORAGE DEVICE, AND ELCTRONIC AND TRANSPORT DEVICES PANASONIC CORPORATION (JP) 2010-08-05 US disclosed
US-7629400-B2 Image making medium HYMAN SYDNEY 2009-12-08 US disclosed
WO-2009118990-A1 ELECTRODE ACTIVE MATERIAL FOR ELECTRICITY STORAGE DEVICE, ELECTRICITY STORAGE DEVICE, ELECTRONIC DEVICE AND TRANSPORT DEVICE パナソニック株式会社 (JP) 2009-10-01 WO disclosed
US-20080248583-A1 Quantitative and Qualitative Chelation Measuring Methods and Materials ALBION LABORATORIES, INC. (US) 2008-10-09 US disclosed
US-20080248583-A1 Quantitative and Qualitative Chelation Measuring Methods and Materials ALBION LABORATORIES, INC. (US) 2008-10-09 US disclosed
US-20080248583-A1 Quantitative and Qualitative Chelation Measuring Methods and Materials ALBION LABORATORIES, INC. (US) 2008-10-09 US disclosed
US-20030035917-A1 Image making medium HYMAN SYDNEY (US) 2003-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297789-A1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES RNASE1, IAPP, TESK1 CA1 2725/4885CA2 3443/4885CA7 2412/4885
US-20100196758-A1 ELECTRODE ACTIVE MATERIAL FOR POWER STORAGE DEVICE, POWER STORAGE DEVICE, AND ELCTRONIC AND TRANSPORT DEVICES CXCR5, CX3CR1, CCR7 CA1 1072/4885CA2 1782/4885CA7 771/4885
US-20140114068-A1 INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES RNASE1, IAPP, FOXK1 CA1 2694/4885CA2 3617/4885CA7 2847/4885
US-20080248583-A1 Quantitative and Qualitative Chelation Measuring Methods and Materials AAAS, LIG4, HAMP CA1 1739/4885CA2 2737/4885CA7 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.